Past studies have reported the appearance of cells sharing phenotypic characteristics of gonadotropes and GH cells. During diestrus and early proestrus, a subset of somatotropes (40 -60%) expressed both GH antigens and gonadotropin (LH-␤, LH␤, or FSH-␤) messenger RNAs (mRNAs) or GnRH receptors. More recently, we reported that subsets of gonadotropes identified by LH␤ or FSH␤ antigens expressed GH-releasing hormone (GHRH) binding sites. The present studies were designed to learn if these putative multipotential cells also expressed GH mRNA. Biotinylated sense and antisense oligonucleotide probes were developed and cytochemical in situ hybridization tests were optimized for the detection of GH mRNA with GH, LH␤, and FSH␤ antigens. RNase protection assays were developed with a complementary RNA probe that detected a 380-bp region at the 5Ј end of the GH mRNA. Both the in situ hybridization and RNase protection assays detected changes in expression of GH mRNA during the estrous cycle with the lowest expression occurring during metestrus and peak expression occurring on the morning of proestrus. Cell counts confirmed the results of the RNase protection assays showing that increases in mRNA levels seen from metestrus to proestrus reflected increased percentages of GH mRNA-bearing cells.
differences in expression of GH mRNA; male rat cell populations had higher values than female rats in metestrus, diestrus, or estrus. However, percentages of GH cells in male rats were equal to those from proestrous female rats and levels of GH mRNA were lower in male rats than proestrous females. Dual labeling experiments showed that, in male rats and diestrous, proestrous, or estrous females, GH mRNA was expressed in over 70% of GH cells. Expression of GH mRNA was also found in 50 -57% of cells with LH␤ or FSH␤ antigens in the same groups. The lowest expression was seen in the metestrous groups (30 -40% of GH cells or gonadotropes expressed GH mRNA). Expression of GH mRNA was first increased from metestrus to diestrous largely in GH cells, and slightly in cells with LH␤ antigens. Further increases were seen in GH and LH cells by the morning of proestrus. In contrast, FSH gonadotropes did not show an increased expression of GH mRNA until the morning of proestrus (reaching the same peak reached by LH cells). These data confirm the working hypothesis that a multihormonal cell type develops during diestrus to support both the somatotrope and gonadotrope populations. Collectively, our studies suggest that this multihormonal cell may function to help support the regulatory functions of the gonadotrope during the periovulatory period. In addition, the appearance of significant levels of expression of GH mRNA by male rat gonadotropes suggests that this multihormonal cell may play a role in regulation of the male reproductive system as well. (Endocrinology 141: 1560 -1570, 2000) S TUDIES DURING THE past decade have reported that the expression of GH messenger RNA (mRNA) varies with age, gender and exposure to sex steroids (1) (2) (3) (4) (5) (6) (7) (8) (9) . In rats, GH secretory patterns become sexually dimorphic after the onset of puberty (1) (2) (3) (4) , and studies during the past 30 yr show that this is mediated by the sex steroid environment (3) (4) (5) . Ibrahim et al. (6) , from our laboratory, reported that male rat pituitaries have 30 -36% GH cells, whereas female rat pituitaries may have 26 -28% GH cells (identified by immunolabeling). Removal of steroids by ovariectomy stimulated an increase in the percentages of GH cells after one month to levels like those of the intact male rats. Castration caused a decrease in percentages of GH cells after 1 month to 26 -28% (6) .
Recently, Gonzalez-Parra et al. (7) showed that castration of adult or neonatal rats decreased percentages of GH cells and levels of mRNA for GH and Pit 1, which encodes a transactivating factor for the GH gene. Normal percentages of GH cells and levels of mRNA could be restored if neonatal castrates received testosterone replacement. The mechanisms behind the sexual dimorphism appear to be complex. Gatford et al. (9) tested sex differences in circulating patterns of somatostatin and GH-releasing hormone (GHRH) in growing lambs. In experiments that controlled for sex differences in food intake, they found that rams had higher levels of the following: plasma and pituitary GH, median eminence content of GHRH and somatostatin, GH pulse amplitudes, and integrated plasma GH. However, the steady-state levels of GH mRNA or the portal blood levels of somatostatin did not differ between the sexes. Thus, they concluded that the sex differences may also be driven by GHRH pulses or changes in pituitary sensitivity to the pulses.
Recent studies in our laboratory have provided additional clues to possible cellular mechanisms behind the sexual dimorphism. In the early 1990s, we discovered that, in diestrous and proestrous female rats, 40 -60% of cells with GH antigens expressed gonadotropin ␤ subunit mRNA. These cells contributed significantly to the overall increase in the percentages of gonadotropes seen late in diestrus and early in proestrus (10) . Further tests of females during the same period of the cycle showed that about 30 -38% of cells with GH antigens expressed receptors for GnRH (11) , suggesting that they could function as multipotential gonadotropes. In subsequent studies, we reported that the expression of GnRH receptors by GH cells could be modulated by inhibin (12) or activin (13) . We hypothesized that a subset of somatotropes might be stimulated to support the gonadotrope population (by the production of LH and FSH) and produce a cocktail of hormones that could be used by the ovary or testis. This multihormonal cell might also be a logical cellular site for steroid induced sex differences in the expression of GH.
We recognized, however that the expression of GH antigens cannot be used to prove that the cell produces GH. GH could be present in gonadotropes as a regulatory hormone bound to receptors or GH binding proteins. Therefore, our studies have sought to determine if the multihormonal cells retain their GH phenotype. In recent studies, we reported that cells with gonadotropin antigens expressed GHRH receptors during proestrus, which is an important characteristic of somatotropes (14) . The present report presents parallel studies to learn if these multihormonal gonadotropes express GH mRNA. Biotinylated oligoprobes complementary to GH mRNA were produced and applied to cell populations from male rats and cycling female rats. The cytochemical data were then correlated with RNase protection assays for GH mRNA to learn if the changes in the cell populations corresponded to overall changes in GH mRNA levels in the pituitary. Our studies provide new evidence for the differential expression of GH mRNA during the estrous cycle as well as significant expression of GH mRNA by gonadotropes from both male and proestrous female rats. Furthermore, this report will confirm previous studies that reported sex differences in expression of GH mRNA. However, these differences depend on the stage of the estrous cycle being studied. Male rats express more GH mRNA only if they are compared with females in estrus, metestrus, and diestrus.
Materials and Methods
Pituitary cells from male and cycling female Sprague Dawley rats were used for these studies. The rats were acclimated for 10 days in a constant light controlled environment (10 h on, 14 h off). Cycling female rats were tested daily for the stage of the estrous cycle, by vaginal smears. Male or female rats were killed between 0900 -1000 h. Female rats were candidates after each had completed at least two normal 4-day cycles. The Animal Use and Care (ACUC) Protocol has been approved annually by the University ACUC committee. All experiments sampled 5-7 rats/ experimental group.
Rats were killed by decapitation within seconds of removal from their cages. The pituitaries were then removed and placed in defined medium as previously described (10) . They were dissociated and the cells were plated overnight in defined media (10) .
For the RNase protection assays, normally cycling female or male rats were killed as described above. Their pituitaries were collected and stored in RNAlater (Ambion, Inc.), a solution that protects cellular RNA from degradation. At the time of extraction, RNAs from each pituitary were extracted with RNAwiz (Ambion, Inc.) according to manufacturer's instructions. Typical yields were 30 -50 micrograms RNA per pituitary.
In situ hybridization
The protocol for in situ hybridization is described in two recent techniques papers (15, 16) . The probe for GH was an oligonucleotide synthesized with biotin attached to the 5Ј end (DNA International, Inc.). It was complementary to mRNA encoding amino acids 40 to 54 on the GH molecule. This is a region that carries no homology with PRL. The biotinylated sense oligonucleotide sequence was also produced and used as a control probe.
The pituitary cells were fixed in 2% glutaraldehyde as described previously (10) . They were then stored for use in the in situ hybridization protocol for no longer than a week. Prehybridization steps were as described in techniques papers 15 and 16 and the cells were incubated with the probes overnight at 37 C. The biotinylated sense and antisense probes were then detected by antibody to biotin in a sandwich technique that ultimately used streptavidin peroxidase as the reporter molecule (15, 16) . This produced a sensitive blue-black reaction in patches or linear patterns in the cell.
In parallel experiments, cells were labeled for the GH mRNA, after which the population was prepared for dual labeling for LH␤, FSH␤, or GH antigens. The immunocytochemical technique was identical to that described previously (15) (16) (17) (18) . It produced an orange-amber reaction product that usually filled the entire cytoplasm.
Counts of at least 150 cells/slide provided the quantitative data for the in situ hybridization studies. Each set of counts represented cell populations from three different slides. Each experimental group was repeated at least three times with two rats/group. We calculated percentages of cells that contained label for GH mRNA with or without label for one of the antigens as described in previous studies (10, 11) . ANOVA (1ϫ) was run to compare averages from each set of rats (n ϭ at least three groups) and, if the F value was significant (P Ͻ0.05), the Fisher's least significant difference post hoc test was run to identify the values that were different.
To detect differences in density or area of label, the threshold density of the GH mRNA label was first established with a Bioquant Windows 95 computer-based densitometer (R & M Biometrics, Nashville, TN). This provided automatic measurements of the area of the label in each cell as well as the average density of the pixels on a scale of 0 -255, where 0 is maximal density (no light transmitted) and 255 is the lowest density (maximal light transmitted). The light meter was set to the same reading each day, and the first 25 labeled cells/coverslip were analyzed. Periodic checks of the threshold were done to highlight the pixels over the label. This helped ensure that all label was detected. During each measurement, the area of the cell was calculated after drawing around its perimeter. Then, the computer automatically calculated the density of label inside the cell. Area of label was calculated by the "video count" reading that provided the number of pixels that covered label for GH mRNA. The area of these counts was calculated automatically. These measurements were done only on cell populations that were exposed to single labeling protocols. Averages were obtained for each experimental group (sampling 4 rats/group), and the averages for the diestrous and proestrous populations were compared by Student's t test. A P Ͻ 0.05 was considered significant.
Assays for pituitary GH mRNA
Production of the cRNA probes. To make the GH cRNA probe, we chose the 5Ј end of rat GH cDNA as a template. This 380-bp fragment was first removed from pRGH-1 (ATCC) by PstI and KpnI digestion, and then inserted into pBluescript II SK (ϩ) (Stratagene, pBSGH). The design ensured that the GH fragment was under the control of the T7 promoter in an antisense orientation. The resulting pBSGH plasmid was amplified in Escherichia coli DH 5␣, and purified with QIAGEN Plasmid Midi kit (QIAGEN). An aliquot of pBSGH was linearized with BamHI, and then purified using QIAquick PCR Kit (QIAGEN) to remove the salt and enzymes.
32 P-labeled antisense RNA probes and RNA markers were produced using a MAXIscript T7 in vitro transcription kit (Ambion, Inc.) according to manufacturer's instruction. The GH cRNA probe was made with the use of the linearized pBSGH as a template. In addition, pTRI-RNA-28S purchased from Ambion, Inc. was applied to make a 28S probe, which targets cellular 28S rRNA. We chose 28S as an internal control for quantitative studies since it is rarely influenced by changes in cell stages or different tissues. RNA Century Marker Templates (Ambion, Inc.) were used for the synthesis of labeled RNA that provided molecular size standards.
Initially, the conditions for the production of the labeled probe were optimized by varying the concentrations of labeled vs. unlabeled UTP in the reactions. Concentrations of 3.1 m of ␣-32 P-UTP and 50 m of unlabeled UTP were found to be optimal for the synthesis of the GH rRNA probe. Similarly, 0.625 m of labeled and 500 m of unlabeled UTP were optimal for the 28S probe. Both GH and 28S probes were gelpurified to ensure the recovery of only full length probes.
The Ribonuclease protection assay (RPA). The RPA was performed using the RPA III kit (Ambion, Inc.). In the initial phases of the study, pilot experiments were set up to determine the optimal ratios between the amounts of sample RNA and radiolabeled probes. This was done by applying pituitary RNA ranging from 0.25 g to 10 g in these pilot RPAs with a constant amount of radiolabeled GH or 28S probe. Our preliminary study indicated that 1 g of pituitary total RNA is sufficient for the detection of GH mRNA by RPA. The specificity of the GH rRNA probe was verified by size fragmentation on a polyacrylamide gel, as well as by RPA run on samples of yeast RNA or on samples that omitted the target RNA.
After the pilot studies optimized the reaction conditions and also showed the specificity of the reaction, GH mRNA was assayed following detailed procedures described in the kit instruction. Briefly, 1 g of sample RNA plus 10 g of yeast RNA (for expansion) were mixed with 4 ϫ 10 4 cpm of GH probe and 2 ϫ 10 4 cpm of 28S probe. After ethanol precipitation, they were resuspended in 10 l of the kit hybridization buffer and incubated at 56 C for about 19 h. Unhybridized RNAs and probes were then digested with RNase A/RNase T1 at a dilution of 1:100 at 37 C for 30 min. Following RNase inactivation and precipitation, sample pellets were resuspended in 10 l of Gel Loading Buffer II, and then run on a 5% acrylamide/8 m urea gel at 200 V for 1.5 h. Autoradiography was carried out by exposing the gel to an x-ray film with an intensifying screen at Ϫ70 C for 1-1.5 h. The radioactive signals on the gel were also quantified by an automated system, InstantImager (Packard Instrument Co., Meriden, CT). The intensity of signals for GH mRNA was depicted as cpm and normalized against signals for 28s rRNA.
Results

Analysis of in situ hybridization labeling for GH mRNA
Counts of single labeled fields showed that male rat pituitaries contained 30.9 Ϯ 3% cells with GH mRNA. (Fig. 1 ). This value is significantly higher than those from metestrous (14.9 Ϯ 0.7%) or estrous (23 Ϯ 3%) females. Diestrous or proestrous female rats had comparable percentages of GH mRNA-bearing cells (29 Ϯ 3%). When the biotinylated sense sequence was substituted for the antisense sequence, the percentages of labeled cells averaged 3 Ϯ 1.5% (three separate experiments, cells from male rats). Cells exposed to hybridization buffer alone during the hybridization had minimal labeling (1.5-2.4%; examples from all sexes and experimental groups). Figure 1 also shows the counts of GH antigen-bearing cells from these same groups (taken from the dual-labeling experiments). Male rats had 35.7 Ϯ 1.4% GH cells. Female rats had percentages of GH cells that ranged from 26 Ϯ 1.4% (metestrous rats) to 34.7% (proestrous rats). The application of the Student's t test showed that metestrous female rats had significantly lower percentages of GH cells when compared with male rats (P Ͻ 0.01) or proestrous female rats (P Ͻ0.05). Figure 2 is a plate that illustrates the GH mRNA labeling data. As in our previous studies (10), the label is in dark spots or lines in the cells and it varies in density from cell to cell. Figure 2d shows that the expression in proestrous females compares favorably with that in the male rats (Fig. 2a) . Figure  2e shows that the expression in some regions from metestrous rat populations is virtually absent. In other fields, there are only one to two cells.
Correlative RNase protection assays
RNase protection assays were applied to total RNA purified from additional pituitaries from the same experimental groups to learn if the changes in percentages of GH mRNA bearing cells reflected changes in overall levels of GH mRNA. Figure 3 shows an autoradiogram that includes some of the tests of specificity of the antisense RNA probes following the manufacturer's instructions. Lane B shows a strong signal on the gel when 10 g yeast RNA was hybridized with 4 ϫ 10 4 cpm of the GH probe and no RNase treatment was used (Lane B). In contrast, Lane A shows that, when RNase A/RNase T1 at 1:100 was added to digest all nonhybridized RNAs, it completely abolished the signal, indicating that no hybrids had formed from the yeast RNA and the GH probe. The 400-bp band seen in Lane B includes both the 380-bp GH probe fragment and 20-bp of flanking sequences from the pBluescript II SK (ϩ) plasmid. Lane C contains a distinctive band (380-bp) from a sample containing total RNA (from male rat pituitary) and the GH probe. The sample was treated with RNase, and the radioactive band indicates that hybrids had formed. The extra bands are believed to be a nonspecific background. This is most likely due to the excess amount of probes used to ensure a quantitative analysis. Lane D shows the effect of adding a sample containing male rat pituitary RNA without the GH probe. No signal was detected when 1 g of total RNA from a male rat pituitary was digested with the same amount of RNase in the absence of the GH probe. Values are lower than all other groups (a). Percentages of GH mRNA-bearing cells from rats in estrus are lower than those from male or female rats (diestrus and proestrus) (b). Student's t test showed that populations from metestrus rats had lower percentages than those from proestrous female or male rats (c).
Figure 4a illustrates a representative autoradiogram showing samples containing total rat pituitary RNA plus GH and 28S probes (and RNase A/RNase T1 treatment) from each experimental group. The quantification of RNA from at least six rats/experimental group is shown in Fig. 4b . The statistical analysis shows that levels of GH mRNA in male rats are Figure 2 illustrates two GH mRNA-bearing cells (also shown in inset) after exposure to 10 nM biotinylated oligonucleotide complementary to GH mRNA. b and c, Fields from male rat cells following exposure to the same amount of biotinylated sense sequence. The field in 2b is a higher magnification of an area from Fig. 2c . Figure 2d shows a field from proestrous rat pituitaries labeled with the biotinylated antisense probe for GH mRNA. GH mRNA bearing cells are noted by arrows (and the inset). The counts of GH mRNA-bearing cells are comparable to those in the male rat (Fig. 2a) . A field from metestrous rat pituitaries is shown in Fig. 2e . The inset shows one of the cells (arrowhead) that has a gray label. In another cluster of cells (arrowhead) there are small patches of label in the cells. However, overall labeling is significantly reduced in the metestrous group. a, c, and d, Magnification, 451ϫ, bar ϭ 10 m; inset magnification, 902ϫ; b, magnification 825ϫ; e, magnification 1155ϫ; inset magnification 1546ϫ. Bar, 10 m.
greater than those in diestrous, metestrous, and estrous female rats. However, proestrous female rats have higher levels of GH mRNA than all other groups, including male rats. Metestrous rats contain levels of GH mRNA that are lower than all but the estrous group.
Densitometric analysis of GH mRNA in individual cells
The RPA data suggested that the rise in levels of GH mRNA peaks at proestrus; however, the cell counts in Fig. 1 indicate that similar percentages of GH mRNA-bearing cells are found in diestrous and proestrous groups. Densitometric analyses were conducted to learn if the difference in levels assayed by the RPA reflected lower levels of GH mRNA/cell. Table 1 shows that values were higher in proestrous rats for all types of measurements, including average areas of GH mRNA bearing cells, average areas of label for GH mRNA/ cell, and the average density of the label. When evaluating density measurements, it is important to note that a lower number reflects less light transmitted. Therefore, labeling density that is more intense (darker blue or black) would let less light through and give a reading closer to 0. Weaker labeling would let more light through and give a higher value in the reading.
Identity of cell types expressing GH mRNA: analysis of dual labeling
Dual labeling showed that changes in expression of GH mRNA occurred in cells with GH or gonadotropin antigens. Figure 5 shows that over 70 -80% of cells with GH antigens expressed GH mRNA in all groups, except metestrous females. Fewer than 30% of GH antigen-bearing cells expressed GH mRNA in the metestrous rats, which is significantly lower than values from all other groups.
To see the impact of the changes on the entire pituitary cell population, the data are also calculated as the percentage of dual labeled cells/total pituitary cells. Figure 6 shows that, in metestrous rats, cells with GH antigens and GH mRNA are only 7% of the pituitary cells. In contrast, these dual-labeled cells represent 22-29% of pituitary cells in all other groups.
Among gonadotropes in male rats, over half of the cells with LH␤ antigens (55%) and 50% of those with FSH␤ antigens expressed GH mRNA (Fig. 7) . In metestrous females, only 30 -35% of cells with FSH␤ or LH␤ antigens contained GH mRNA. Expression of GH mRNA by LH cells rose significantly during diestrus to reach a peak of 57% of cells with LH␤ antigens by the morning of proestrus, and it remained high during estrus. Cells with FSH antigens exhibited a slightly different pattern. The rise to 57% of FSH cells did not occur until the morning of proestrus, and this peak level persisted until the morning of estrus (which is not different from the values in proestrous rats).
Because they have actively secreted their stores, percentages of immunoreactive gonadotropes are at their lowest during metestrus (7%, 10, 17, 18) . Therefore, the dual labeling data were also calculated as percentages of dual labeled cells/total pituitary cells to show the impact of the changes in gonadotropes on the entire pituitary population (Fig. 8) .
In male rat populations, 6 -7% of the pituitary cells contain LH␤ or FSH␤ antigens and GH mRNA. Metestrous populations have only 2.5-2.75% cells dual labeled for gonadotropin antigens and GH mRNA. The percentages of cells with GH mRNA and LH␤ antigens rise rapidly during diestrus to reach a peak of nearly 11% of the pituitary population by the morning of proestrus. A slower rise is seen in percentages of cells with GH mRNA and FSH␤ antigens, although the peak values reached by the morning of proestrus are similar. This is followed by a decline in percentages during estrus to 4.5% cells with FSH␤ antigens and GH mRNA and 6% cells with LH␤ antigens and GH mRNA.
Finally, the data also calculated changes in percentages of GH mRNA-bearing cells that contained each of the antigens tested. Figure 9 shows the data. In all stages of the cycle but estrous, over 90% of GH mRNA bearing cells had translated the mRNA and stored GH antigens. During metestrus, this Figure 10 is a plate illustrating examples of dual-labeled cells. Figure 10 , a and b, compares fields labeled for GH mRNA and GH antigens in metestrous (Fig. 10a) and proestrous (Fig. 10b) rats. Fewer dual labeled GH cells are seen in the metestrous field as would be expected from the values in Fig. 9 . In contrast, numerous cells with GH mRNA and/or GH antigens are evident in the field from proestrous rats (10b). Figure 10c shows a cell with GH mRNA and LH␤ antigens in the metestrous field. It is extending a process and strands of linear arrayed label are evident in the cytoplasm. The field in 10d illustrates a cell with GH mRNA and LH␤ antigens (also shown in the inset). Also illustrated are two cells with label for GH mRNA only (gray label). Figure 10 , e-g, are views from male rats taken with oil immersion objectives to show examples of the differential labeling patterns. Figure 10e shows two labeled cells. One cell is labeled intensely gray for GH mRNA next to a cell labeled orange for LH␤ and black for GH mRNA. Faint orange label is seen in the adjacent cell when one focuses through the gray label. Figure 10f is also from male rats and shows a cell labeled gray for GH mRNA (with a faint orange for LH antigens) and another cell labeled dense orange for LH␤ and black for GH mRNA (in a linear pattern). Figure 10 g shows a view of the circular pattern of label for GH mRNA (vacuoles) in a cell that contains GH antigens. Figure 10h shows three labeled cells from proestrous rats. Two of the cells are labeled orange for FSH␤ only. The cell in the center contains FSH␤ antigens and a dense patch of label for GH mRNA.
Discussion
The present study adds further information about common phenotypic characteristics shared by members of the somatotrope and gonadotrope populations. This phenomenon was first described in 1994 when we demonstrated the transient expression of LH␤ and FSH␤ mRNA (10) and GnRH receptors (11) by cells with GH antigens during diestrus that reached a peak during proestrus. Later studies showed that the rise in expression of GnRH receptivity by cells with GH antigens could be mimicked by treating diestrous rat pituitary populations with activin (13) .
In our earlier studies (10, 11), we recognized that the pres- ence of GH antigens in the putative multihormonal cell did not necessarily prove that the cells were somatotropes. We reasoned that GH could be present in gonadotropes as a regulatory hormone bound to GH binding proteins (reviewed in Ref. 11) . Therefore, during the past 3 years, we have continued to look at the extent to which gonadotropes might express characteristics unique to GH cells, to learn more about the significance of this coexpression of GH and gonadotropin hormones and receptors. The first studies of GH cell phenotypes showed that GHRH binding sites could be found on GH cells and gonadotropes (14) . We also reported that the highest expression however, the label is so faint for GH in three of the cells that it cannot be detected well in the low magnification view (also shown in inset). One of the cells also has GH mRNA (cell a) and one of the cells shows labeling for GH only (cell b). Cell a is also shown in inset. b, Stronger label for GH mRNA in proestrous rats. Most of the labeled cells have a blend of label for GH mRNA and antigens which gives them a muddy appearance in the low magnification views. The inset shows that two of the cells in the cluster have black linear patterns for the GH mRNA label. c and d, Fields labeled for GH mRNA and LH␤ antigens from metestrous (c) and proestrous (d) populations. Only one labeled cell is seen in the field in c, and it shows a linear and patchy label for GH mRNA (black) in a cell with orange label for LH␤. The cell has extended a process, a feature that is typical of gonadotropes (also shown in the inset). In d, three labeled cells are evident. The cell that contains both GH mRNA (black patch or line) and LH␤ antigens is also shown in the inset. This cell also has extended a process. Cells labeled gray for GH mRNA are also seen in the field (arrows). e-h, Added to illustrate the differential labeling pattern from these groups. Label for GH mRNA and LH␤ antigens in male rat cells is seen in e and f. e, Shows one cell densely labeled for GH mRNA (gray) with some faint orange label seen (out of the focal plane). It lies adjacent to a cell with dense orange label for LH␤ that also includes patches of black label for GH mRNA. Another cell contains dense gray label and faint orange label for the same combination of hormones. g, Shows that the label for GH mRNA appears in vacuoles around the central nucleus (n). This cell (from a male rat) is also labeled orange for GH. h, Dual labeling for GH mRNA (black) and FSH in one of the three cells taken from a proestrous rat. All three cells contain orange label for FSH, but only one shows dense black label for GH mRNA. a and b, Magnification 451ϫ, bar ϭ 10 m; inset magnification 902ϫ; c and d, magnification 825ϫ, bar ϭ 10 m; inset magnification 1,155ϫ; e-h, magnification 1,546ϫ, bar ϭ 5 m.
of GHRH receptors by cells with gonadotropin antigens occurs in early proestrus, when the putative multihormonal cells emerge. Significant numbers of gonadotropes in male rats (20 -30% of gonadotropes) also expressed GHRH. The presence of GHRH receptors added support for the hypothesis that the cells were somatotropes and not gonadotropes with endocytosed GH antigens. It also added information suggesting that these cells could respond to multiple secretagogues.
The findings from the present study provide the strongest support for the hypothesis that the multihormonal cells represent a unique subset that functions to support both the GH and gonadotrope population. In all but the metestrous groups, over 91% of the mRNA-bearing cells contain GH antigens (Fig. 9) . At the same time, 41% or 32% of GH mRNAbearing cells contain LH␤ or FSH␤ antigens, respectively. Adding these percentages accounts for over 100% of the GH mRNA cell population. Therefore, it is likely that 30 -40% of these GH mRNA-bearing cells are multipotential and can store all three hormones. These data correlate well with percentages published in 1994 (10) , which showed that 40% of cells with GH antigens contain LH␤ mRNA and 34% of cells with GH antigens express GnRH receptors (11) .
At this point, there are four combinations of phenotypes found in these pituitary cells that point to a multihormonal function for this subset. These include expression of: GH antigens with LH␤ or FSH␤ mRNAs (10); GH antigens and GnRH receptors (11-13); GHRH receptors and LH␤ or FSH␤ antigens (14) ; and GH mRNA and LH␤ or FSH␤ antigens (the present report). A fifth phenotypic characteristic common to this subset is the response to inhibin and activin (12, 13) , which decreases or increases expression of GnRH receptors in GH cells, respectively.
Sexual dimorphism in expression of GH mRNA
Sexual dimorphism appears during pubertal development (1-4) and, as discussed in the introduction, removal of steroid feedback produces expression of GH mRNA or antigens more like that in the opposite sex (6, 7) . Similarly, restoration of steroid feedback allows recovery to the sex-specific level of expression (7). The results from this study also partially confirm studies that show sexual dimorphism in the expression of GH mRNA by adult rat pituitaries (7, 8, 19) . However, in our experiments, the female rats were separated into groups based on the stage of the estrous cycle. New findings in the present study show that male rat pituitaries have more GH mRNA only when compared with female rats in metestrus, diestrus, or estrus. Because none of the previous studies of adult rats identified the stage of the cycle (7, 8, 19) , it is likely that they assayed GH mRNA in a mixed group of females that might contain proestrous rats in a minority of the population.
Differential expression of GH mRNA during the estrous cycle
Both the RNase protection assays and counts from the in situ hybridization studies agree that there is an increase in GH mRNA transcripts (or their stability) when metestrous and proestrous groups are compared. However, the RNase protection assays showed intermediate values in the diestrous group, whereas the counts from in situ experiments showed maximal percentages of cell labeled for GH mRNA. Densitometric studies were then done to learn if the differences between the assays were due to changes in the amount of GH mRNA/cell (as detected by area and density). The stereometric and densitometric data showed that GH mRNA bearing cells from proestrous rats were larger and contained more GH mRNA (detected by area and density) than their counterparts from diestrous rats.
The current study is the first to show differential expression of GH mRNA during the estrous cycle. Past studies of the expression of GH secretory activity using reverse hemolytic plaque assays (20) showed no changes in the number of GH-secreting plaques with the bovine estrous cycle. Indeed, most studies that have counted percentages of GH cells in the cycling female rat have reported no significant differences (10, 11) . The present studies reported differences in GH antigen-bearing cells only when values from metestrous rats were compared with those from males and proestrous female rats.
This study also is the first to show that differences in GH mRNA are expressed by cells bearing GH or gonadotropin antigens. The lowest expression of GH mRNA was in both GH cells and gonadotropes during metestrus. The first increase in GH mRNA-bearing cells during diestrus came from cells that stored GH antigens as well as those storing LH␤ antigens. The timing of the increase in expression varied with the cell type, however. This suggests a sequence of events that may underlie the differentiation of this multihormonal cell.
Proposed steps toward differentiation of the multihormonal subset
Significant changes in GH mRNA appeared first in the GH cell population early in diestrus. This is seen as an increase in expression of GH mRNA from 30% of GH cells during metestrus to 70% of GH cells by the morning of diestrus. GHRH is known to be an important regulator of the synthesis of GH mRNA (21-30). These data suggest that the GHRH-GH cell axis may be triggered early in the cycle to stimulate an increase in GH mRNA synthesis.
Comparing these results with those in the previous study (10) also showed that this increased transcriptional activity from metestrus to diestrus occurs before the appearance of significant numbers of GH cells with LH or FSH mRNAs. Hence, the data suggest that GH mRNA is the first product from this multihormonal subset. At the same time, however, there is a significant increase in the percentages of LH cells with GH mRNA. Thus, collectively this suggests that the diestrous multihormonal cells are producing three products: GH and LH antigens and GH mRNA.
In our 1994 studies (10), we showed that 30% GH cells (defined by antigen content) begin to express GnRH receptors (11) late in diestrus. These data are consistent with a multihormonal cell type that contains LH antigens. Thus, by late diestrous, we hypothesize that a fourth product (GnRH receptors) is made that allows the population to respond to GnRH pulses. On the morning of proestrus, there is an ex-pansion in the population of cells with GH antigens and LH␤ and FSH␤ mRNA. The timing of appearance suggests that the GnRH receptors produced during the previous 12 h have allowed the expression of gonadotropins that eventually reach a peak of 12.5%-15% of pituitary cells by the afternoon of proestrus (10) .
Finally, the present studies show some nonparallelism when LH and FSH cells are compared. Whereas LH cells show an increase in GH mRNA during diestrus, the same change is not seen in FSH cells until proestrus. Furthermore, during peak expression periods late in proestrus, FSH is found in a higher percentage of GH cells (60%) than LH (40%, 10). Collectively, these findings suggest the later appearance of a subset of GH-FSH bearing cells. Perhaps these cells support unique FSH functions during early estrous.
Significance of the appearance of the multihormonal cells
The significance of the coexpression of GH and gonadotropins may be related to their ability to secrete a "cocktail" of hormones needed by the gonads, including GH. In 1993, Blumenfeld presented evidence that GH plays a role in ovulation induction. He suggested that GH may be a "co-gonadotropin" because it adds to or synergizes with gonadotropins (31). There is evidence that GH is involved in a variety of ovarian functions (31-36). In a recent review Adashi (37) cited several studies showing that GH is therapeutic in humans, particularly in hypogonadotropic conditions. For example, GH may play a permissive role in the onset of puberty. Also, patients resistant to ovulation induction therapy could ovulate if given GH.
In rodents, human GH (hGH) prolongs the cycles (from 5 to 10 days) and the period of fertility (37). In addition, partial suppression of endogenous GH secretion resulted in delayed puberty in female rats. Rat GH replacement therapy increased ovarian progesterone production (in response to gonadotropins) and allowed normal puberty to occur. Finally, GH replacement therapy restored follicular development in some GH deficient mice (reviewed in Ref. 37). Recent studies of the Wistar derived dwarf rat reported that rhGH therapy restored the reduced ovarian weights and promoted development of intermediate follicles (38) . The phenotypic defects in the reproductive system of these GH-deficient animals (39, 40) and the fact that some defects can be corrected with GH therapy (37, 38, 41, 42) points to the importance of GH in normal development of sperm and ovarian follicles.
To summarize, this study has added more information about the GH phenotypic characteristics shared by subsets of GH and gonadotropin cells in adult pituitaries. The study shows that gonadotropes may express significant levels of GH mRNA in both male and female rats, especially females in early proestrus. This supports the working hypothesis that the multihormonal cell is derived from a subset of cells that can express normal somatotropic and gonadotropic phenotypes. It adds information about the significant expression of GH mRNA in male rat gonadotropes that suggests that GH may be important in the regulation of the male reproductive system as well. The appearance of this multihormonal cell may not be solely the result of GH binding and endocytosis by gonadotropes as was suggested after our 1994 studies (10, 11), although autocrine or paracrine regulation by GH cannot be ruled out (43, 44).
Finally, the study confirms sex differences in the expression of GH mRNA reported previously, but only if male rats are compared with females rats in metestrus, diestrus, or estrus. This study is also the first to show differential expression of GH mRNA during the estrous cycle that suggests that expression might be regulated by hormones in the reproductive axis. Because the sex differences in GH expression are clearly affected by changing the steroid feedback (gonadectomy), this presents candidate hormones for further tests of this hypothesis. 
